Core Viewpoint - BioSig Technologies, Inc. has regained compliance with Nasdaq listing requirements, allowing its common stock to continue trading on The Nasdaq Capital Market [1][2][3] Company Compliance - On March 24, 2025, BioSig received confirmation from Nasdaq that it met the minimum stockholders' equity threshold of $2.5 million, resolving a previously disclosed deficiency [2] - The company is now in full compliance with all applicable Nasdaq continued listing standards [2] Leadership Statement - CEO Anthony Amato expressed satisfaction with the company's regained compliance, emphasizing a commitment to corporate governance and financial stability [3] - The company aims to deliver long-term value to shareholders and is focused on advancing operational goals and strengthening market position [3] Strategic Focus - BioSig is committed to innovation, strategic partnerships, and investments in advanced technologies to meet shareholder expectations [3] - Further details on specific initiatives and partnerships will be announced as they progress [3] Company Overview - BioSig Technologies is a medical device technology company with the PURE EP™ Platform, which enhances signal processing for electrophysiologists in treating cardiovascular arrhythmias [4][5] - The PURE EP™ Platform allows for real-time acquisition of raw signal data, improving procedural success and efficiency [5]

Revenue Performance - Revenue for the three months ended September 30, 2024 was $0, compared to $1 for the same period in 2023, indicating a significant decline in recognized service revenue [203]. - Revenue for the nine months ended September 30, 2024 was $27, compared to $6 for the same period in 2023 [217]. Acquisitions and Business Development - The company announced the intent to acquire Neuro-Kinesis Corporation, with a purchase price involving the issuance of shares and potential cash contributions of $2.5 million to $6 million [176]. - The company plans to hire 4-6 additional employees to support business development and commercialization of the PURE EP System, contingent on funding availability [200]. - The company expects to incur additional marketing and commercialization expenses related to the PURE EP system, along with increased general and administrative expenses as it expands [247]. Financial Condition and Compliance - The company has been notified of non-compliance with Nasdaq listing requirements, including a minimum bid price of $1.00 per share and a market value of listed securities of at least $35 million [179][181]. - The company has received a grace period until March 7, 2025, to regain compliance with Nasdaq's market value listing requirements [185]. - The company’s common stock began trading on the OTCQB on July 23, 2024, after being delisted from Nasdaq [185]. - The accumulated deficit as of September 30, 2024 was $254.24 million, with expectations of continued losses until products reach full commercial profitability [241]. - The company has incurred net losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern [242]. Expenses and Financial Performance - Research and development expenses for Q3 2024 were $156, a decrease of $989 or 86.38% from $1,145 in Q3 2023 [206]. - General and administrative expenses for Q3 2024 were $2,763, a decrease of $52 or 1.85% from $2,815 in Q3 2023 [208]. - Payroll related expenses increased to $1,744 in Q3 2024 from $1,302 in Q3 2023, an increase of $442 or 33.95% [209]. - Net loss attributable to common shareholders for Q3 2024 was $1,940 compared to a net loss of $4,569 in Q3 2023 [216]. - Research and development expenses for the nine months ended September 30, 2024 were $736, a decrease of $3,180 or 81.21% from $3,916 in the same period in 2023 [220]. - General and administrative expenses for the nine months ended September 30, 2024 were $10,559, a decrease of $7,608 or 41.88% from $18,167 in the same period in 2023 [222]. - Net loss attributable to common shareholders for the nine months ended September 30, 2024 was $9,395 compared to a net loss of $22,999 in the same period in 2023 [233]. - Cash used in operations for the nine months ended September 30, 2024 was $4,284, a decrease from $14,371 in the same period in 2023 [239]. Legal Matters - The company received a threat of litigation on December 4, 2023, seeking $775,782 for alleged wrongful termination, which was concluded to be without merit [277]. - A second threat of litigation was received on February 22, 2024, claiming losses of $1,440,000 due to unlawful actions by the board of directors, which the company believes is also without merit [278]. - A lawsuit was filed on March 22, 2024, seeking at least $288,000 in damages related to stock certificate issuance, which the company intends to contest vigorously [279]. - The company believes that the final disposition of legal proceedings should not have a material adverse effect on its financial position or results of operations [280]. - The company is unable to provide an evaluation of the outcome of ongoing litigation or estimate potential losses at this time [279]. - The company has moved to dismiss the claims made by the plaintiff in the recent lawsuit, with a hearing set for September 2024 [279]. - There are no material proceedings involving directors, officers, or significant shareholders that are adverse to the company's interests [281]. Internal Controls and Management - Management identified material weaknesses in internal control over financial reporting, including inadequate identification and reporting of stock-based compensation [271]. - The company intends to add sufficient staff and oversight controls in 2025 to remediate identified deficiencies in internal controls [272]. - The company may experience negative impacts on its ability to accurately report financial results due to material weaknesses in internal controls [273]. - Management has remediation plans that will be implemented in 2025 to address identified weaknesses [275]. - There have been no changes in internal control over financial reporting that materially negatively affected the company during the last completed fiscal quarter [275]. Funding and Capital Requirements - The company completed a securities purchase agreement on May 1, 2024, selling 783,406 shares at $1.4605 per share, raising a total of $1,144,164 [190]. - The company raised gross proceeds of approximately $3.0 million from a registered direct offering and concurrent private placement on May 30, 2024 [253]. - A promissory note for $500,000 was issued on March 7, 2024, with a 12% interest rate due in 2026 [254]. - Future capital requirements will depend on various factors, including the progress of research and development and the timing of regulatory approvals [248]. - The company may need to delay or reduce research and development programs if additional financing is not available on acceptable terms [250]. Strategic Focus - The company plans to shift focus from technology development to commercialization, resulting in meaningful reductions in annual expenses [243].

Core Viewpoint - BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum bid price requirement, indicating a positive development for the company's stock status [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on enhancing intra-cardiac signal visualization, particularly in heart rhythms, through innovative software solutions [3]. - The company's FDA 510(k) cleared PURE EP™ Platform offers superior real-time signal visualization, improving the efficiency and efficacy of cardiac ablation procedures [4]. Compliance Achievement - To regain compliance, BioSig's common stock needed to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved as of November 13, 2024 [2]. - Nasdaq has closed the prior bid price deficiency matter, confirming the company's compliance status [2]. Leadership Statement - The CEO of BioSig expressed gratitude for the support received during the relisting process and emphasized the company's commitment to increasing shareholder value [3].

Core Insights - BioSig Technologies, Inc. successfully appealed to the NASDAQ Panel, allowing its common stock to resume trading on the NASDAQ Capital Market Exchange starting October 23, 2024 [1] - The company received an extension until March 7, 2025, providing a 360-day grace period for compliance with the Market Value of Listed Securities requirement [1] Company Overview - BioSig Technologies is a medical technology company focused on enhancing the accuracy of intra-cardiac signal visualization, particularly in heart rhythms [2] - The company utilizes a unique software platform to provide clear cardiac signal clarity, addressing significant healthcare challenges such as time, cost, and life-saving measures [2] Product Information - The FDA 510(k) cleared PURE EP™ Platform offers superior real-time signal visualization, enabling physicians to conduct targeted cardiac ablation procedures with improved efficiency and efficacy [3]

Financial Performance - Revenue for the three months ended June 30, 2024, was $13, compared to $0 for the same period in 2023, indicating a significant increase in recognized service revenue[148] - Net loss attributable to common shareholders for the three months ended June 30, 2024 was $3,918 compared to a net loss of $11,096 for the same period in 2023[154] - Revenue for the six months ended June 30, 2024 was $27, compared to $5 for the same period in 2023[155] - Other income for the six months ended June 30, 2024 totaled $1,403, an increase of $1,621 over the expense of $(218) incurred in the same period in 2023[163] - Cash used in operations for the six months ended June 30, 2024 was $2,795, a decrease from $10,543 in the same period in 2023[167] Expenses - Research and development expenses decreased by $1,367, or 79.99%, to $342 for the three months ended June 30, 2024, down from $1,709 in the same period of 2023[149] - General and administrative expenses were $4,914 for the three months ended June 30, 2024, a decrease of $4,193 or 46.04% from $9,107 in the same period of 2023[150] - Payroll related expenses decreased to $3,971 from $5,936, a decrease of $1,965, or 33.11%[151] - Research and development expenses for the six months ended June 30, 2024 were $580, a decrease of $2,191, or 79.07% from $2,771 for the same period in 2023[156] - General and administrative expenses for the six months ended June 30, 2024 were $7,796, a decrease of $7,556 or 49.22% from $15,352 for the same period in 2023[157] - Stock-based compensation for research and development personnel decreased from $761 in Q2 2023 to $133 in Q2 2024[149] Workforce and Operations - The company has reduced its workforce significantly, laying off 16 employees in January 2024 and an additional 26 employees in February 2024 due to funding issues[140] - The company is currently operating with only 5 employees and 6 key consultants, with plans to hire 4-6 additional staff depending on funding[144] Legal Matters - The company received a threat of litigation on December 4, 2023, with a claim for $775,782, which was concluded to be without merit[200] - Another threat of litigation was received on February 22, 2024, seeking restitution for losses totaling $1.44 million, which the company believes is without merit[201] - Plaintiff Michael Gray Fleming filed a lawsuit against the Company seeking at least $288,000 in damages related to stock certificate issuance[202] - The Company believes the allegations are baseless and intends to contest them vigorously[202] - A hearing for the motion to dismiss the Plaintiff's claims is scheduled for September 2024[202] - The Company does not anticipate that the final disposition of other legal proceedings will materially affect its financial position or results of operations[203] - There are no material legal proceedings involving directors, officers, or significant shareholders that are adverse to the Company's interests[203] Capital and Funding - The company announced the intent to acquire Neuro-Kinesis Corporation, with a potential cash contribution of $2.5 million to $6 million upon closing[132] - On January 12, 2024, the company raised gross proceeds of $1.04 million by selling 260,720 shares of common stock and warrants[178] - On May 1, 2024, the company raised $1.14 million by selling 783,406 shares of common stock and warrants, including $634,999 in cash[179] - On May 30, 2024, the company closed an offering raising approximately $3.0 million for working capital and general corporate purposes[181] - A promissory note for $500,000 was issued on March 7, 2024, with a 12% interest rate due in 2026[182] Internal Controls and Compliance - Management identified material weaknesses in internal control over financial reporting, including inadequate identification and reporting of stock-based compensation[193] - The company’s common stock was delisted from Nasdaq due to non-compliance with minimum stockholders' equity requirements, and it is now trading on the OTC Markets[137] Future Outlook - The company expects to incur losses from operations in the near future, with increased marketing, commercialization, and R&D expenses related to the PURE EP system[174] - Future capital requirements will depend on R&D progress, regulatory approvals, and competitive product status[175] Intellectual Property - The company currently holds 41 issued/allowed utility patents and has 27 additional patent applications pending related to the PURE EP System[133]

Acquisition Intent - BioSig Technologies has executed a non-binding letter of intent to acquire the assets of Neuro-Kinesis Corporation (NKC), with the purchase price to be paid through the issuance of BioSig's common stock [1][8] - NKC will provide BioSig with a minimum of $2.5 million and potentially up to $6 million in unrestricted cash at closing [1] Management and Expertise - NKC is managed by a team of seasoned professionals with extensive backgrounds in medical technology, electrophysiology, clinical research, regulatory affairs, and technology commercialization [3] - The management team includes notable figures such as Josh Shachar, the CEO, and Dr. Eli Gang, the Chief Medical Officer, who bring significant expertise in their respective fields [24][25] Technology Overview - NKC's Huygens™ Catheter aims to improve the resolution of signal detection in electrophysiology (EP) procedures, addressing limitations of current mapping technologies [23] - The Proteus™ Robotic Arm enhances catheter navigation, providing precision control during EP diagnostic procedures [16][30] - The Huygens™ Catheter incorporates micro-electronics for signal amplification and digital processing, reducing noise contamination and improving signal clarity [28] Market Potential - The acquisition is expected to accelerate the market entry of NKC's breakthrough technology for diagnosing and treating complex cardiac arrhythmias [9] - NKC's technology is positioned to address the needs of the 35% of patients suffering from complex arrhythmias, where traditional ablation therapies are often ineffective [14][23] Future Developments - NKC plans to develop automated EP mapping systems utilizing AI-based applications to enhance the efficiency and efficacy of EP procedures [32] - The company holds an extensive portfolio of 47 issued patents related to its catheter and robotic arm technologies, along with nearly 200 additional patents in the smart surgical device arena [31]

This limited or inaccurate mapping is especially true for any signal capture that occurs in the lower ranges below 100µV (microvolts), which leads to the second problem. Most simple arrhythmia issues are found to be in the area above the 100µV range and as high as 1000µV. These large signals are easily able to be seen above the noise threshold so the EP physician can determine where ablation can be effective. But for the 35% of patients who suffer from complex arrhythmias, traditional ablation therapy is no ...

One substantial savings recognized is for the successful termination of the office lease expense for the former headquarters in Westport, Connecticut as of July 15, 2024 which was set to end on December 31, 2024. BioSig's CEO, Anthony Amato stated, "Maintaining a strong and flexible balance sheet is a priority for our new management team. In a difficult market for companies like ours, we look for other ways to help our company and its shareholders. This reduction will provide more flexibility in evaluating ...

Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at ...

Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at ...